Interesting
https://articles.mercola.com/sites/articles/archive/2022/01/22/genocide.aspx?ui=ff340c8dbd45cc819d4a24e4c8404772abc3ca8f52ef1a47742a0bc8bfe56f7a&sd=20150731&cid_source=dnl&cid_medium=email&cid_content=art1ReadMore&cid=20220122&mid=DM1097187&rid=1386497641

I can’t wait for a marjac victory to straighten these numbers out. (Damn spellcheck)

They must have some data by now? would think if good they would have to stop trial? Here's hoping results are promising

FFS
If breakaway gaps don't get filled, why has this stock fallen all the way from 25+ after R-it to a recent low of 3.11, only 9 or 12 cents from filling the gap, depending on how you measure it (hi-lo or close-open). My limited experience is all gaps get filled, with few exceptions. For instance, a take-out offer gap doesn't get filled unless the deal goes sour.

FFS,
1) I am not a TA.
2) I appreciate the work you do and your posts.
3) This stock is going nowhere until the Sept 24, 2019 gap is filled which means until we get a print at $2.99 (hopefully on a large block) this stock is going to continue to flounder in the low 3s.
4) The sooner the better, hopefully prior to 2/11/22.

They must be racing each other to the bottom.

It's amazing how all of this software has enabled managers to do the work of a competent secretary.

I consider both to be evil, along with Dr. Fauci.

If astaxanthin can, why not Vascepa?:

https://articles.mercola.com/sites/articles/archive/2022/01/18/how-to-prevent-a-cytokine-storm.aspx?ui=ff340c8dbd45cc819d4a24e4c8404772abc3ca8f52ef1a47742a0bc8bfe56f7a&sd=20150731&cid_source=dnl&cid_medium=email&cid_content=art3ReadMore&cid=20220118&mid=DM1093735&rid=1382780777

Recent statin study review:
https://media.mercola.com/ImageServer/Public/2022/January/PDF/statins-do-more-harm-than-good-pdf.pdf

Must see if true:
https://articles.mercola.com/sites/articles/archive/2022/01/13/melatonin-reduces-covid-mortality.aspx?ui=ff340c8dbd45cc819d4a24e4c8404772abc3ca8f52ef1a47742a0bc8bfe56f7a&sd=20150731&cid_source=dnl&cid_medium=email&cid_content=art1HL&cid=20220113_HL2&mid=DM1089650&rid=1378090708

https://finance.yahoo.com/news/amarin-corporation-plc-amrn-fell-171118152.html

what is the usual time period between the NICE meeting and the published decision?

5.02 broken on 2/11/22?

EU not a catalyst but a long drawn out process that they may blown this morning in UK

ditto

Of all the catalysts that could appreciatively move this stock (not including an unforeseen BO) marjac's effort stands out as the best-remaining hope. And I think he will succeed, certainly as regards standing (24), but also the whole enchilada (60).

When will we know UK decision?

Why the F did this stupid management fail to bring Bhatt to this meeting? Inexcusable. Really stupid, especially if they had any whiff that Nissen might be there. This management is pathetic from Eckman on down. Clowns.

Who is paying Nissen to pooh-pooh Vazkepa at the hearing, and why? Is he doing this out of the kindness of heart? Malevolent loser.

With luck, they could have UK approval to talk about. though I'm not sure of UK proceedures.

marjac,
If we win rule 24 standing, Hikma’s defense of rule 60 seems to be extremely difficult if not a lost cause. Can they derail the rule 60 proceedings by reaching some type of settlement with Amarin? I don’t trust Amarin management to reach an agreement that would be satisfactory to most retail shareholder. I would hope we can proceed with rule 60 to a satisfactory conclusion with highly compensatory damages.

Will UK approve Vazkepantomorrow? Who knows, but with the China delay, matjac’s effort becomes the seminal event in Amarin’s future. If we get rule 24 standing we have some hope (slim) for the future, otherwise grab your ankles and kiss your Amarin goodbye.

Once marjac wins rule 60, what damages are we seeking from Hikma? May I suggest 3 x the $2.5 billion market cap lost on 3/30/20 after the decision was published, payable directly to shareholders of record on 3/29/20, not to the company for management to abscond with.

What are you seeing?

Not how I had pictured him in my mind, but he looks much more intelligent than KM and JT combined. And probably the parade of ner do we’ll lawyers that preceded him. Go get ‘‘em marjac.

thanx rafun

marjac,I know this does not need to be said, but be prepared for a lot of rule 60 questions on Feb. 11. It does not seem to me that this shareholder lawsuit is so unique as to require a rule 24 hearing. After all shareholders have long been recognized as plaintiffs in many cases. I’m hoping we get a good panel that is more interested in the basis of our suit— fraud upon the court.

What is the status of the GSK/Teva suit? I have lost track with all the other law suits pending.

Will any of these provide lift-off?
Jan. 11, JPMorgan presentation.
(German sales insights?)
Jan. 11, UK label hearing/approval.
Jan. 31, China label approval (finally?)
Feb. 11, Rule 24 oral argument.
Feb. 15, mutual fund holdings.
(Denner holdings)
Feb. 25, Amarin Conference Call ?
Feb. 28, MITIGATE primary completion date.

Hopefully all of these bode well for this sick stock!

https://www.healtheuropa.eu/amarin-changing-the-landscape-of-residual-cardiovascular-disease-risk/112160/

When I thought my AMRN investment would pay off handsomely, so did I,. Now not so much.

https://investor.amarincorp.com/news-releases/news-release-details/amarin-present-40th-annual-jp-morgan-healthcare-conference

Thanks for posting. I read this article months ago, very interesting.

CB, what do we need to do to listen to marjac and rule24/60 hearing Feb 11?

Marjac this may sound like a back handed complement, but I thank God you were caught like the rest of us by DU’s very erroneous patent decision. Without you and your very well written.rule24/60 briefs I would have very little hope of recouping my losses and reaping a small gain in this stock. I may be a Pollyanna but I am of the opinion this ordeal will be decided and over in our favor by the second quarter of this year. Thank you for your hard work and diligence on our behalf. I hope you are well rewarded, financially, emotionally and psychologically. And please know most of us are grateful in the extreme.

X3?

No, you are right of course, my number would be easy to compute while other lost sales would be subjective and subject to arbitration or, worse more court battles.